A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,110

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Malaria, Falciparum
Interventions
DRUG

ACT

"1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days"

DRUG

TACT

"1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."

Trial Locations (20)

Unknown

College of Medicine Chittagong, Rāmu

Ann Hospital, Ann Town

Pyay hospital, Prome

Pyin oo Lwin hospital, Pyin Oo Lwin

Thabeikkyin hospital, Thabeikkyin

Pailin, Pailin

Preah Vihear, Preah Vihear

Pursat, Pursat

Ratanakiri, Ratankiri

Kinshasa, Kinshasa

Ispat General hospital, Rourkela

Mohanpur Community health center, Agartala

Midnapore, Medinīpur

Sekong, Sekong

Phusing hospital, Phusing

Tha Song Yang hospital, Tha Song Yang

Chumphon hospital, Chumphon

Kunhan Hospital, Si Sa Ket

Thanto Hospital, Yala

Binh Phuoc hospital, Bình Phước

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02453308 - A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC) | Biotech Hunter | Biotech Hunter